Cytek Biosciences, Inc. CTKB Business Segments — Total stock-based compensation
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Cytek Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytek Biosciences, Inc.'s business segments — total stock-based compensation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytek Biosciences, Inc.'s business segments — total stock-based compensation?
- Cytek Biosciences, Inc. (CTKB) reported business segments — total stock-based compensation of $4.86M in Q1 2026.
- How has Cytek Biosciences, Inc.'s business segments — total stock-based compensation changed year-over-year?
- Cytek Biosciences, Inc.'s business segments — total stock-based compensation decreased by 26.7% year-over-year, from $6.63M to $4.86M.
- What is the long-term trend for Cytek Biosciences, Inc.'s business segments — total stock-based compensation?
- Over 3 years (2022 to 2025), Cytek Biosciences, Inc.'s business segments — total stock-based compensation has grown at a 14.0% compound annual growth rate (CAGR), from $16.59M to $24.59M.
- What does business segments — total stock-based compensation mean?
- Represents the total non-cash expense recognized for equity-based awards granted to employees and management within the segment. This metric is essential for understanding the dilution impact and the total cost of human capital.